Source abstract
Abstract
Human pluripotent stem cells harbor an unlimited capacity to generate therapeutically relevant cells for applications in regenerative medicine. However, to utilize these cells in the clinic, scalable culture systems that activate defined receptors and signaling pathways to sustain stem cell self-renewal are required; and synthetic materials offer considerable promise to meet these needs. De novo development of materials that target novel pathways has been stymied by a limited understanding of critical receptor interactions maintaining pluripotency. Here, we identify peptide agonists for the human pluripotent stem cell (hPSC) laminin receptor and pluripotency regulator, α6-integrin, through unbiased, library-based panning strategies. Biophysical characterization of adhesion suggests that identified peptides bind hPSCs through α6-integrin with sub-μM dissociation constants similar to laminin. By harnessing a high-throughput microculture platform, we developed predictive guidelines for presenting these integrin-targeting peptides alongside canonical binding motifs at optimal stoichiometries to generate nascent culture surfaces. Finally, when presented as self-assembled monolayers, predicted peptide combinations supported hPSC expansion, highlighting how unbiased screens can accelerate the discovery of targeted biomaterials.
Source: openalex_inverted_index · Quality: baseline
Affiliations
Department of Bioengineering, University of California, Berkeley, Berkeley, California 94720, United States
Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, California 94720, United States
Department of Materials Science and Engineering, University of California, Berkeley, Berkeley, California 94720, United States
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California 94720, United States
Funding
National Eye Institute · Division of Graduate Education · Thomas and Stacey Siebel Foundation · Rogers Family Foundation · Jan Fandrianto Chair Fund